- Home
- PEN vs BBIO Comparison
PEN vs BBIO Comparison
Compare PEN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- BBIO
- Stock Information
- Founded
- PEN 2004
- BBIO 2015
- Country
- PEN United States
- BBIO United States
- Employees
- PEN N/A
- BBIO N/A
- Industry
- PEN Medical/Dental Instruments
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PEN Health Care
- BBIO Health Care
- Exchange
- PEN Nasdaq
- BBIO Nasdaq
- Market Cap
- PEN 10.6B
- BBIO 9.4B
- IPO Year
- PEN 2015
- BBIO 2019
- Fundamental
- Price
- PEN $272.98
- BBIO $51.21
- Analyst Decision
- PEN Strong Buy
- BBIO Strong Buy
- Analyst Count
- PEN 16
- BBIO 16
- Target Price
- PEN $302.93
- BBIO $64.44
- AVG Volume (30 Days)
- PEN 457.5K
- BBIO 2.2M
- Earning Date
- PEN 10-29-2025
- BBIO 11-11-2025
- Dividend Yield
- PEN N/A
- BBIO N/A
- EPS Growth
- PEN 916.05
- BBIO N/A
- EPS
- PEN 3.74
- BBIO N/A
- Revenue
- PEN $1,280,152,000.00
- BBIO $235,812,000.00
- Revenue This Year
- PEN $15.52
- BBIO $115.49
- Revenue Next Year
- PEN $14.20
- BBIO $64.61
- P/E Ratio
- PEN $72.91
- BBIO N/A
- Revenue Growth
- PEN 12.92
- BBIO 7.62
- 52 Week Low
- PEN $184.80
- BBIO $21.72
- 52 Week High
- PEN $310.00
- BBIO $54.60
- Technical
- Relative Strength Index (RSI)
- PEN 56.68
- BBIO 52.92
- Support Level
- PEN $270.54
- BBIO $52.20
- Resistance Level
- PEN $288.91
- BBIO $54.60
- Average True Range (ATR)
- PEN 7.36
- BBIO 2.26
- MACD
- PEN -0.15
- BBIO -0.06
- Stochastic Oscillator
- PEN 41.57
- BBIO 56.48
About PEN Penumbra Inc.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.